MNLO - Menlo Therapeutics: Strong Amzeeq Launch Recent Zilxi Approval And Positive FCD105 Results Point To Growth Ahead
Since January of this year, shares of Menlo Therapeutics (MNLO) (formerly Foamix) have been cut by roughly two-thirds, given the fallout of the Coronavirus pandemic, as well as the lackluster result of the merger between Foamix and Menlo to form the newly combined company. With the failure of serlopitant, the former Menlo lead product, the merger felt like “much ado about nothing”, despite an improvement in the balance sheet. On April 6 and 7, MNLO shares fell 60% on the negative serlopitant news, with investors ignoring the other assets in the company. We